생물학적 제제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Biologics Market size is expected to reach USD 1567.34 Billion in 2034 from USD 640.20 Billion (2025) growing at a CAGR of 10.46% during 2026-2034.

The Global Biologics Market is growing significantly due to rising demand for advanced therapies to treat chronic and complex diseases. Biologics, including monoclonal antibodies, vaccines, and recombinant proteins, have transformed treatment approaches in oncology, autoimmune disorders, and infectious diseases. Increasing prevalence of lifestyle-related illnesses and higher healthcare expenditure are contributing to strong market expansion.

Primary growth drivers include advancements in biotechnology and improved manufacturing processes. The expansion of biosimilars has also enhanced market accessibility and affordability in several regions. Growing investments in research and development, along with strong clinical pipelines, are further supporting innovation in biologic drug development globally.

Future prospects remain highly promising as next-generation biologics, including gene and cell therapies, gain traction. Expanding healthcare infrastructure in emerging economies will open new growth avenues. Technological improvements in large-scale production and cold chain logistics are expected to enhance distribution efficiency. The continued focus on personalized medicine will further solidify biologics as a dominant segment in the pharmaceutical industry.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Source

• Microbial
• Mammalian
• Others

By Product

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense & RNAi Therapeutics
• Others

By Disease Category

• Oncology
• Infectious Diseases
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

By Manufacturing

• Outsourced
• In-House

COMPANIES PROFILED

• Samsung Biologics, Amgen Inc, Novo Nordisk AS, AbbVie Inc, Sanofi, Johnson Johnson Services Inc, Celltrion Healthcare Co Ltd, BristolMyers Squibb Company, Eli Lilly and Company, F Hoffmann LaRoche Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOLOGICS MARKET: BY SOURCE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source
• 4.2. Microbial Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOLOGICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Recombinant Proteins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Antisense & RNAi Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOLOGICS MARKET: BY DISEASE CATEGORY 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Category
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Immunological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cardiovascular Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Hematological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOLOGICS MARKET: BY MANUFACTURING 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Manufacturing
• 7.2. Outsourced Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. In-House Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOLOGICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Source
  • 8.2.2 By Product
  • 8.2.3 By Disease Category
  • 8.2.4 By Manufacturing
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Source
  • 8.3.2 By Product
  • 8.3.3 By Disease Category
  • 8.3.4 By Manufacturing
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Source
  • 8.4.2 By Product
  • 8.4.3 By Disease Category
  • 8.4.4 By Manufacturing
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Source
  • 8.5.2 By Product
  • 8.5.3 By Disease Category
  • 8.5.4 By Manufacturing
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Source
  • 8.6.2 By Product
  • 8.6.3 By Disease Category
  • 8.6.4 By Manufacturing
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BIOLOGICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Samsung Biologics
  • 10.2.2 Amgen Inc
  • 10.2.3 Novo Nordisk A/S
  • 10.2.4 AbbVie Inc
  • 10.2.5 Sanofi
  • 10.2.6 Johnson & Johnson Services Inc
  • 10.2.7 Celltrion Healthcare Co. Ltd
  • 10.2.8 Bristol-Myers Squibb Company
  • 10.2.9 Eli Lilly And Company
  • 10.2.10 F. Hoffmann La-Roche Ltd